Limited microbiome sample size, which restricted statistical power and the depth of microbial diversity analysis.

The sponsor faced significant observational errors due to reliance on self-reported pain and stiffness scores, leading to inconsistent efficacy interpretation.

IBS-D studies often show inconsistent outcomes due to high placebo effects and subjective symptom reporting variability.

A major challenge in dry eye clinical research is distinguishing true physiological improvement from placebo-related symptom relief.

Weight-loss trials often suffer from placebo-related bias due to heightened participant motivation and self-report variability.

In the diabetic neuropathy trial, subjective pain scales (VAS, NPSI) fail to capture true functional recovery.

The client’s geriatric study relied on self-reported mobility and strength, leading to subjective bias, high data variability, and weak differentiation between treatment and placebo arms.

The client wanted to evaluate whether 5-ALA + SFC supplementation could strengthen the immune response after COVID-19 vaccination. However, antibody kinetics after vaccination vary widely among individuals, and prior exposure or suboptimal immune activation often leads to inconsistent antibody titres and unclear efficacy outcomes.

In a vascular function study, FMD results showed high variability due to unregulated caffeine intake and inconsistent meal timings affecting vascular tone and nitric oxide response.

A CNS trial for a focus-enhancing compound showed high placebo response on attention tasks, making it difficult to distinguish genuine treatment effects from expectancy bias.